Sukumar Ethirajan, MD
Hematology & Oncology · Overland Park, KSNPI 1396716056
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,159 of the $61,346 with a category attached, or 68.7%. 31 manufacturers reported payments, led by Bayer at 38.5% of the total. Reporting peaked in 2021 at $23,922 and has fallen 97.3% since, to $639 in 2025.
Across 386 payments — averaging $158.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$24K
- Roche Molecular Systems, Inc.$12K
- Novartis$10K
- Pfizer$5K
- Dendreon Pharmaceuticals LLC$4K
- AstraZeneca$2K
- plus $4K from 25 others
What the payments were for
- Consulting fees$42,15969%
- Speaking & faculty fees$6,31010%
- Travel & lodging$3,5896%
- Food & beverage$8,87514%
- Education$4131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 28 | $23,623 |
| Roche Molecular Systems, Inc. | 12 | $12,386 |
| Novartis | 45 | $10,294 |
| Pfizer | 78 | $5,336 |
| Dendreon Pharmaceuticals LLC | 30 | $3,513 |
| AstraZeneca | 4 | $2,008 |
| Johnson & Johnson | 67 | $1,497 |
| Astellas Pharma US Inc | 34 | $874 |
| AbbVie | 21 | $344 |
| Blue Earth Diagnostics | 19 | $316 |
| E.r. Squibb & Sons, L.L.C. | 3 | $209 |
| Merck | 6 | $187 |
| Amgen | 9 | $167 |
| Janssen Scientific Affairs, LLC | 2 | $81 |
| Ferring Pharmaceuticals Inc. | 4 | $71 |
| Myovant Sciences Inc. | 4 | $53 |
| Urogen Pharma, Inc. | 1 | $52 |
| BD | 1 | $42 |
| Eisai Inc. | 3 | $39 |
| Exelixis Inc. | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 2 | $30 |
| Tolmar, Inc. | 1 | $29 |
| Myriad Genetic Laboratories, Inc. | 2 | $26 |
| Sanofi | 1 | $22 |
| Foundation Medicine, Inc. | 1 | $19 |
| Axonics, Inc. | 1 | $17 |
| Accord Healthcare, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $16 |
| Telix Pharmaceuticals | 1 | $15 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,346 in reported general payments places this provider in the 85th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 1,540 | $21,463,865 |
| NubeqaDarolutamide | 941 | $12,459,778 |
| ErleadaApalutamide | 209 | $3,021,696 |
| OrgovyxRelugolix | 710 | $1,853,549 |
| Abiraterone Acetate | 923 | $1,472,515 |
| LynparzaOlaparib | 50 | $820,435 |
| TalzennaTalazoparib Tosylate | 17 | $307,658 |
| YonsaAbiraterone Acet,submicronized | 19 | $187,743 |
| Prednisone | 937 | $7,304 |
| Bicalutamide | 33 | $558 |
| Methylprednisolone | 22 | $477 |
| Alendronate Sodium | 47 | $394 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $874 | $21,463,8651,540 claims |
| BayerNubeqa | $23,623 | $12,459,778941 claims |
| Johnson & JohnsonErleada | $1,497 | $3,021,696209 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $81 | $1,472,515923 claims |
| AstraZenecaLynparza | $2,008 | $820,43550 claims |
| PfizerTalzenna | $5,336 | $307,65817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 97 hematology & oncology providers in Kansas.
Other hematology & oncology in Overland Park
- Marc HoffmannOverland Park$153K
- Dhruv BansalOverland Park$79K
- Joseph StilwillOverland Park$2K
- Gregory CraneOverland Park$2K
- Richard McKittrickOverland Park$1K
- Rachana YendalaOverland Park$1K
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Priyanka SharmaWestwood$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.